Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab CYP Interaction Study in CD/UC
NCT03358706Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of ustekinumab in Crohn's disease and ulcerative colitis (UC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Geometric Mean Ratio (Day 22/ Day 1) of the Maximum Plasma Concentration (Cmax) of Cytochrome P450 Probe Substrates, Geometric Mean Ratio (Day 113/ Day 1) of the Maximum Plasma Concentration (Cmax) of Cytochrome P450 Probe Substrates and 2 more. Started Feb 2018; status: terminated.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03358706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358706.